Current Edition

clinical

OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Early Stage Prostate Cancer

Opthea Recruits 176th Patient and On-Track to Report Primary Data Analysis Early 2020 OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company …

Continue Reading →